No Data
No Data
Quoin Pharmaceuticals at Risk of Nasdaq Delisting Amidst Financial Challenges
Maxim Group Maintains Quoin Pharmaceuticals(QNRX.US) With Buy Rating, Maintains Target Price $2
Promising Developments and Financial Stability Propel Quoin Pharmaceuticals' Buy Rating
Quoin Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Quoin Pharmaceuticals Reports Q3 EPS ($1.63), Consensus (49c)
Quoin Pharmaceuticals Continues to Evaluate M&A Opportunities
No Data
No Data
Millionaire one day : 🫡🫡